CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 06/11/2021

CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 06/11/2021

Have a nice dry weekend. 

NEW YORK TIMES WINS PULITZER PRIZE FOR PUBLIC SERVICE FOR ITS COVID COVERAGE

(J. Harris: Good. They deserved it. Their fabulous writers surround, explore,  and prod problems and  then disseminate information better than any  news, social, or governmental organization of which I am aware. If I could only read one “thing” daily, it would be the Times. I rarely read their editorials; I love their sports department, which for over ten years has been hammering away at Chronic Traumatic Encephalopathy (CTE) and for which they deserve another Pulitzer Since early 2020, this paper has provided the best Covid-19 coverage that I have found. Over about the last six months, they have become so adept that they save me an hour or two on most days while I try to keep up with the local ramifications of the Pandemic. CONGRATULATIONS NEW YORK TIMES.

FROM HOPKINS CITATIONS:

1. Mixing COVID-19 Vaccines Appears to Boost Immune Responses (Science) Faced with short supplies of COVID-19 vaccines and unforeseen side effects, some countries have adopted an unproven strategy: switching shots midstream. Most authorized vaccines require two doses administered weeks or months apart, but Canada and several European countries are now recommending a different vaccine for the second dose in some patients. Early data suggest the approach, born of necessity, may actually be beneficial.

2.No Health Issues in Babies Whose Moms Got Flu Vaccine While Pregnant (CIDRAP) Infants who were exposed to the flu vaccine in utero—meaning their mothers received the vaccine while pregnant—did not have an increased likelihood of adverse outcomes, according to a study today in JAMA. The study looked at more than 99% of live births during the 2010-11 to 2013-14 flu seasons in Nova Scotia, Canada.

Underlying Medical Conditions Associated With Severe COVID-19 Illness Among Children

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.  [PFIZER VACCINE]

Our estimation of 51% vaccine effectiveness against PCR-confirmed SARS-CoV-2 infection and 54% vaccine effectiveness against symptomatic infection 13 to 24 days after immunization with first dose of BNT162b2 provides critically needed evidence on the early performance of BNT162b2 vaccine in real life and has some important implications in decision-making to prevent transmission of SARS-CoV-2 and control the pandemic. While these results are encouraging, the BNT162b2 vaccine should be administered in a 2-dose regimen 21 days apart, as licensed for emergency use approval, to achieve maximum protection and impact in reducing the burden of COVID-19 and possibly the transmission of SARS-CoV-2.

(J. Harris: A study from Israel shows TAKE BOTH JABS!)

5 Facts About Covid Vaccines

(J. Harris: Good general and readable article to send to the unvaccinated wary.)

AND LAST BUT NOT LEASED:

My Norwegian Housekeeper is back to work with her new hip. Here she is helping in the garden.

Maybe she’ll be cooking again soon?

As far as the garden in concerned, I’ve not had to water in a month. Unfortunately, some of the tomatoes that I planted early and surrounded by old newspapers, developed non-venereal root rot. The leaves yellowed and died, the stems turned black and dreary and the tomatoes quit growing. I cut off the bad leaves and removed the newspapers to let things dry out. I was not surprised when I noticed that all of the sick plants had been covered by Longview News. The plants protected by Marshall News Messenger were in semi-perfect. condition! Strangely, a couple of plants on the far left side of the garden that were covered by New York Times, must have caught on fire and were charred. I don’t know what all  of this means, and I was a scientist or sorts. I kid you not. J. Harris

***********************************

GIVE US YOUR FEEDBACK.  CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.

Click here to submit feedback.  Let us know what you think.

click here to CLOSE THIS PAGE